SA521421375B1 - عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها - Google Patents

عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها

Info

Publication number
SA521421375B1
SA521421375B1 SA521421375A SA521421375A SA521421375B1 SA 521421375 B1 SA521421375 B1 SA 521421375B1 SA 521421375 A SA521421375 A SA 521421375A SA 521421375 A SA521421375 A SA 521421375A SA 521421375 B1 SA521421375 B1 SA 521421375B1
Authority
SA
Saudi Arabia
Prior art keywords
group
substitution
unit
alkyl
drug
Prior art date
Application number
SA521421375A
Other languages
Arabic (ar)
English (en)
Inventor
وو كون-ليانج
جين كينجو
دوبليداي وينديل
Original Assignee
سياجن إنك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سياجن إنك. filed Critical سياجن إنك.
Publication of SA521421375B1 publication Critical patent/SA521421375B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SA521421375A 2018-09-07 2021-03-03 عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها SA521421375B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862728639P 2018-09-07 2018-09-07

Publications (1)

Publication Number Publication Date
SA521421375B1 true SA521421375B1 (ar) 2024-02-11

Family

ID=68000124

Family Applications (1)

Application Number Title Priority Date Filing Date
SA521421375A SA521421375B1 (ar) 2018-09-07 2021-03-03 عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها

Country Status (17)

Country Link
US (1) US20230002440A1 (enExample)
EP (1) EP3847161A1 (enExample)
JP (1) JP7511543B2 (enExample)
KR (1) KR20210073525A (enExample)
CN (1) CN112996778A (enExample)
AU (1) AU2019336231A1 (enExample)
BR (1) BR112021004317A2 (enExample)
CA (1) CA3111149A1 (enExample)
EA (1) EA202190699A1 (enExample)
IL (1) IL281090A (enExample)
MA (1) MA53550A (enExample)
MX (1) MX2021002570A (enExample)
SA (1) SA521421375B1 (enExample)
SG (1) SG11202102126VA (enExample)
TW (1) TWI825169B (enExample)
UA (1) UA128730C2 (enExample)
WO (1) WO2020051503A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020482800B2 (en) * 2020-12-23 2025-08-21 Genequantum Healthcare (Suzhou) Co., Ltd. Novel isomeric compounds comprising a ring-opened thiosuccinimide group, an oligopeptide fragment and a chiral moiety
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2148886B1 (en) * 2007-05-10 2014-02-19 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
MA50124A (fr) * 2017-09-08 2020-07-15 Seattle Genetics Inc Procédé de préparation de tubulysines et d'intermédiaires de celles-ci

Also Published As

Publication number Publication date
EP3847161A1 (en) 2021-07-14
MA53550A (fr) 2021-12-15
EA202190699A1 (ru) 2021-06-08
CN112996778A (zh) 2021-06-18
JP7511543B2 (ja) 2024-07-05
TWI825169B (zh) 2023-12-11
WO2020051503A1 (en) 2020-03-12
KR20210073525A (ko) 2021-06-18
CA3111149A1 (en) 2020-03-12
US20230002440A1 (en) 2023-01-05
AU2019336231A1 (en) 2021-03-18
TW202024043A (zh) 2020-07-01
BR112021004317A2 (pt) 2021-05-25
JP2021536475A (ja) 2021-12-27
SG11202102126VA (en) 2021-04-29
IL281090A (en) 2021-04-29
UA128730C2 (uk) 2024-10-09
MX2021002570A (es) 2021-06-08

Similar Documents

Publication Publication Date Title
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
PH12020551716A1 (en) Anti-ror antibody constructs
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2023002507A (es) Inhibidores de cd73.
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX393879B (es) Métodos de preparación de niraparib.
JOP20190155A1 (ar) مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
WO2015164392A8 (en) Novel anti-rnf43 antibodies and methods of use
WO2020008377A3 (en) Ionic self-assembling peptides
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
WO2018067520A3 (en) Therapeutic agents and methods:
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
EP4331622A3 (en) Integrin binding peptides and uses thereof
EP4467138A3 (en) Therapeutic agents for neurodegenerative diseases
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2020001928A (es) Proceso para la preparacion de tubulisinas e intermediarios de las mismas.
SG11201907914QA (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
MX2021002570A (es) Procesos alternativos para la preparacion de tubulisinas e intermediarios de las mismas.
WO2020049598A3 (en) Apalutamide polymorphs
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.